BMO Capital analyst Evan David Seigerman raised the firm’s price target on Merck to $113 from $102 and keeps a Market Perform rating on the shares. With Keytruda the key growth driver of 2022 and meaningful indication that expansion is not continuing into 2023, the focus now turns to Merck’s pipeline and newly acquired assets, and the firm is enthusiastic on sotatercept and the recently closed Prometheus transaction as a steps in the right direction, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Johnson & Johnson Stock (NYSE:JNJ): Medicare Negotiations and Q2 Earnings in Focus
- Merck initiated with a Hold at HSBC
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Endo launches first generic version of Merck’s Noxafil in the U.S.
- Kineta to Receive $5M milestone payment from Merck